MedTrace Logo

Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity

NCT05382767 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-03-28

No results posted yet for this study

Summary

Multicenter, randomized, double-blind, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501A in Subjects with Post-stroke Upper Limb Spasticity

Conditions

  • Post-stroke Upper Limb Spasticity

Interventions

DRUG

CKDB-501A

Muscle Spasticity

DRUG

Botox®

Muscle Spasticity

Sponsors & Collaborators

  • CKD Bio Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-02
Primary Completion
2022-12-08
Completion
2022-12-08

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05382767 on ClinicalTrials.gov